(Q42484098)

English

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells

scientific article published on March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 November 2017

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells (English)

1 reference

Europe PubMed Central

1 November 2017

phosphorylation

1 reference

based on heuristic

inferred from title

Józefa Wesierska-Gadek

1

object named as

Józefa Węsierska-Gądek

1 reference

Europe PubMed Central

1 November 2017

author name string

David Gritsch

2

1 reference

Europe PubMed Central

1 November 2017

Nora Zulehner

3

1 reference

Europe PubMed Central

1 November 2017

Oxana Komina

4

1 reference

Europe PubMed Central

1 November 2017

Margarita Maurer

5

1 reference

Europe PubMed Central

1 November 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

1 November 2017

Journal of Cellular Biochemistry

1 reference

Europe PubMed Central

1 November 2017

112

1 reference

Europe PubMed Central

1 November 2017

761-772

1 reference

Europe PubMed Central

1 November 2017

3

1 reference

Europe PubMed Central

1 November 2017

Endocrine-responsive breast cancer and strategies for combating resistance

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Pathology of hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Oestrogen receptors - an overview

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Estrogen activates cyclin-dependent kinases 4 and 6 through induction of cyclin D in rat primary osteoblasts

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Cyclin-dependent kinase inhibitors: a survey of recent patent literature

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Estrogen receptor variants

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Epidemiology of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Estrogen receptor phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Cell cycle kinases as therapeutic targets for cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

The nuclear receptor superfamily: the second decade

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Estrogen signaling: a subtle balance between ER alpha and ER beta

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Breast cancer genetics: what we know and what we need

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Genomic instability--an evolving hallmark of cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

CDK inhibitors: from the bench to clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Role of hormones in mammary cancer initiation and progression

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Cross-talk between peptide growth factor and estrogen receptor signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Inhibition of cyclin-dependent kinases by purine analogues.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Cloning of the human estrogen receptor cDNA

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Uterine estrogen receptor in vivo: phosphorylation of nuclear specific forms on serine residues

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context.

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Whether to target single or multiple CDKs for therapy? That is the question

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Novel potent pharmacological cyclin-dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Ki67 in breast cancer: prognostic and predictive potential

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Cyclin D1 protein expression and function in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCB.23004

21 January 2018

Identifiers

10.1002/JCB.23004

1 reference

Europe PubMed Central

1 November 2017

1 reference

Europe PubMed Central

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42484098&oldid=1959066721"